Kathy D Miller

Summary

Affiliation: Indiana University
Country: USA

Publications

  1. ncbi request reprint A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 11:3369-76. 2005
  2. ncbi request reprint A physiologic imaging pilot study of breast cancer treated with AZD2171
    Kathy D Miller
    Division of Hematology and Oncology, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA
    Clin Cancer Res 12:281-8. 2006
  3. pmc A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109
    Lida A Mina
    Indiana University Melvin and Bren Simon Cancer Center, Indiana Cancer Pavilion, RT 473, 535 Barnhill Dr, Indianapolis, IN, 46202, USA
    Invest New Drugs 31:1307-10. 2013
  4. pmc A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
    K D Miller
    Department of Medicine, Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
    Ann Oncol 23:331-7. 2012
  5. ncbi request reprint A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, Indiana 46202, USA
    Invest New Drugs 22:69-73. 2004
  6. pmc Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
    Kathy D Miller
    Indiana University, Indianapolis, Indiana, USA
    Breast Cancer Res 6:128-32. 2004
  7. ncbi request reprint The role of ErbB inhibitors in trastuzumab resistance
    Kathy D Miller
    Indiana University School of Medicine, Indianapolis, 46202, USA
    Oncologist 9:16-9. 2004
  8. ncbi request reprint Breast cancer: the role of angiogenesis and antiangiogenic therapy
    Kathy D Miller
    Division of Hematology and Medical Oncology, Indiana University, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Hematol Oncol Clin North Am 18:1071-86, ix. 2004
  9. ncbi request reprint Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, IN, USA
    J Clin Oncol 23:792-9. 2005
  10. ncbi request reprint Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory
    Kathy D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA
    Breast Cancer Res Treat 89:187-97. 2005

Detail Information

Publications85

  1. ncbi request reprint A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 11:3369-76. 2005
    ....
  2. ncbi request reprint A physiologic imaging pilot study of breast cancer treated with AZD2171
    Kathy D Miller
    Division of Hematology and Oncology, Department of Medicine, Indiana University, Indianapolis, IN 46202, USA
    Clin Cancer Res 12:281-8. 2006
    ....
  3. pmc A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109
    Lida A Mina
    Indiana University Melvin and Bren Simon Cancer Center, Indiana Cancer Pavilion, RT 473, 535 Barnhill Dr, Indianapolis, IN, 46202, USA
    Invest New Drugs 31:1307-10. 2013
    ..Angiogenesis plays an essential role in tumor development, invasion and metastasis. We evaluated the efficacy and safety of dual angiogenesis blockade with bevacizumab and sorafenib in patients with metastatic breast cancer...
  4. pmc A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
    K D Miller
    Department of Medicine, Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
    Ann Oncol 23:331-7. 2012
    ..E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial...
  5. ncbi request reprint A phase II study of 9-nitro-camptothecin in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, Indiana 46202, USA
    Invest New Drugs 22:69-73. 2004
    ..Pharmacokinetic samples were obtained to investigate the correlation of plasma 9-NC exposure with clinical response and toxicity...
  6. pmc Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?
    Kathy D Miller
    Indiana University, Indianapolis, Indiana, USA
    Breast Cancer Res 6:128-32. 2004
    ..Early enthusiasm for antiangiogenic therapy must give way to clinical reality. Our challenge now is to exploit better the activity of antiangiogenic agents seen in the early clinical studies...
  7. ncbi request reprint The role of ErbB inhibitors in trastuzumab resistance
    Kathy D Miller
    Indiana University School of Medicine, Indianapolis, 46202, USA
    Oncologist 9:16-9. 2004
    ..With a better understanding of the biology of breast cancer, and with several novel ErbB receptor inhibitors in development, continued progress for improved patient outcomes is expected...
  8. ncbi request reprint Breast cancer: the role of angiogenesis and antiangiogenic therapy
    Kathy D Miller
    Division of Hematology and Medical Oncology, Indiana University, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202, USA
    Hematol Oncol Clin North Am 18:1071-86, ix. 2004
    ..Development of targeted antiangiogenic agents provides new challenges to clinical trial design. Current antiangiogenic therapy with traditional agents and novel agents are classified and reviewed...
  9. ncbi request reprint Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, IN, USA
    J Clin Oncol 23:792-9. 2005
    ....
  10. ncbi request reprint Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory
    Kathy D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA
    Breast Cancer Res Treat 89:187-97. 2005
    ..Primary chemotherapy provides an ideal opportunity to correlate potential non-invasive surrogate markers of angiogenesis with tumor microvessel density (MVD) and response...
  11. ncbi request reprint Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
    K D Miller
    Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, IN, USA
    J Clin Oncol 17:3033-7. 1999
    ..To evaluate the efficacy and toxicity of combination and sequential dose-dense chemotherapy with doxorubicin and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) as primary chemotherapy of breast cancer...
  12. ncbi request reprint A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer
    Kathy D Miller
    Indiana University, Indianapolis, Indiana, USA
    Clin Cancer Res 10:1971-5. 2004
    ..This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a matrix metalloproteinase inhibitor (MMPI), into adjuvant breast cancer therapy...
  13. ncbi request reprint Redefining the target: chemotherapeutics as antiangiogenics
    K D Miller
    Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 19:1195-206. 2001
    ..Finally, we describe potential mechanisms of resistance to antiangiogenic chemotherapies-some of which may apply to the pure antiangiogenics currently in development...
  14. ncbi request reprint A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer
    K D Miller
    Indiana University, Indianapolis, IN, USA
    Ann Oncol 13:1220-4. 2002
    ..This pilot trial was performed to evaluate the safety, toxicity and pharmacokinetics of chronic therapy with the matrix metalloproteinase inhibitor marimastat in the adjuvant treatment of breast cancer...
  15. ncbi request reprint Issues and challenges for antiangiogenic therapies
    Kathy D Miller
    School of Medicine, Indiana University, Indianapolis, USA
    Breast Cancer Res Treat 75:S45-50; discussion S57-8. 2002
    ....
  16. ncbi request reprint Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  17. ncbi request reprint E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer
    Kathy D Miller
    Indiana Cancer Pavillion, Indianapolis, IN 46202, USA
    Clin Breast Cancer 3:421-2. 2003
  18. ncbi request reprint Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
    K D Miller
    Division of Hematology and Oncology, Indiana University, Indianapolis, IN 46202, USA
    Ann Oncol 14:1072-7. 2003
    ..As screening central nervous system (CNS) imaging is not routinely performed, the incidence and clinical relevance of occult CNS metastases in advanced breast cancer is unknown...
  19. ncbi request reprint Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide
    Qi Huang Zheng
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Nucl Med Biol 31:77-85. 2004
    ..The results were compared. From our results, we concluded that both [11C]MSMA and [11C]CGS 25966 might be unsuitable as PET tracers for cancer imaging...
  20. ncbi request reprint Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester
    Qi Huang Zheng
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Nucl Med Biol 30:753-60. 2003
    ..These results suggest that the localization of [(11)C]FMAME in the tumor is mediated by non-specific processes, and the visualization of [(11)C]FMAME on the tumor using the Indy-PET II scanner is related to non-specific binding...
  21. ncbi request reprint Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents
    Xiangshu Fei
    Department of Radiology, Indiana University School of Medicine, IN 46202, Indianapolis, USA
    Bioorg Med Chem Lett 13:2217-22. 2003
    ....
  22. ncbi request reprint Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues
    Xiangshu Fei
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 14:1247-51. 2004
    ..The results suggest that the uptakes of [11C]T138067 in both MCF-7 transfected with IL-1alpha tumor and MDA-MB-435 tumor are non-specific binding...
  23. ncbi request reprint Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer
    Min Wang
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 17:332-6. 2007
    ....
  24. ncbi request reprint Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
    Rajasubramaniam Shanmugam
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Prostate 66:1498-511. 2006
    ..Nuclear Factor kappa B (NFkappaB) is a eukaryotic transcription factor that is constitutively active in human cancers and can be inhibited by the naturally occurring sesquiterpene lactone, parthenolide (P)...
  25. doi request reprint Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem 18:2099-106. 2010
    ..Radioligand binding assays indicated compounds 6f, 6b, and 9f display potent in vitro binding affinities with nanomolar K(i) values and at least 100-2000-fold selectivity for CB2...
  26. doi request reprint Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, Room 202, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 21:3222-6. 2011
    ....
  27. ncbi request reprint Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Eur J Med Chem 43:2211-9. 2008
    ..These results encourage further in vivo evaluation of carbon-11 labeled tetrahydroisoquinoline derivatives as new potential SERM radioligands for PET imaging of ER expression in breast cancer...
  28. ncbi request reprint Synthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast cancer estrogen receptors
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L 3 Room 202, Indianapolis, IN 46202, USA
    Appl Radiat Isot 66:523-9. 2008
    ....
  29. ncbi request reprint Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers
    Xiangshu Fei
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Nucl Med Biol 31:1033-41. 2004
    ..2.2 followed by a quick deprotection reaction and purification with the HPLC method in 20-30% radiochemical yields...
  30. ncbi request reprint [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice
    Qi Huang Zheng
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Nucl Med Biol 29:803-7. 2002
    ..These results suggest that [11C]choline may be a potential PET breast cancer imaging agent...
  31. doi request reprint Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Steroids 75:967-73. 2010
    ....
  32. pmc Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Bryan P Schneider
    Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:4672-8. 2008
    ..Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer...
  33. doi request reprint Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer
    Min Wang
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Steroids 74:896-905. 2009
    ..The specific activity at end of synthesis (EOS) was 111-185GBq/micromol...
  34. pmc Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
    Bryan P Schneider
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 19:1281-9. 2013
    ..We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here...
  35. doi request reprint [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 22:1569-74. 2012
    ....
  36. ncbi request reprint Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents
    Min Wang
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem 14:8599-607. 2006
    ....
  37. ncbi request reprint Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8
    Min Wang
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L 3 Room 202, Indianapolis, IN 46202, USA
    Appl Radiat Isot 66:1406-13. 2008
    ....
  38. doi request reprint Synthesis of 2-[11C]methoxy-3,17β-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Steroids 77:864-70. 2012
    ....
  39. ncbi request reprint The role of vascular endothelial growth factor genetic variability in cancer
    Bryan P Schneider
    Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, USA
    Clin Cancer Res 15:5297-302. 2009
    ..If validated, these finding could help direct which subgroup of patients should receive bevacizumab...
  40. doi request reprint The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Nucl Med Biol 37:763-75. 2010
    ..The radiochemical yields were 15-30%, decay corrected to end of bombardment (EOB), based on [(11)C]CO(2). The specific activity was 222-296 GBq/μmol at EOB and 111-148 GBq/μmol at the end of synthesis, respectively...
  41. doi request reprint Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2)
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Appl Radiat Isot 68:1098-103. 2010
    ..The overall synthesis time from EOB was 15-20 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 111-185 GBq/micromol...
  42. doi request reprint Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in cancer
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16 th Street, L3 208, Indianapolis, IN 46202, USA
    Steroids 75:715-20. 2010
    ....
  43. doi request reprint A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
    Lida Mina
    Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Invest New Drugs 27:565-70. 2009
    ..As PKCbeta and PI3K/AKT signaling are both involved in breast cancer pathogenesis, this phase II study evaluated the efficacy and toxicity of enzastaurin in previously treated patients with metastatic breast cancer (MBC)...
  44. doi request reprint Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and cancer
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, Indianapolis, IN 46202, USA
    Appl Radiat Isot 74:61-9. 2013
    ..2.2 via the nucleophilic substitution and isolated by HPLC combined with SPE in 25-40% decay corrected radiochemical yield with 37-222GBq/μmol specific activity at EOB...
  45. doi request reprint Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha)
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 208 Indianapolis, IN 46202, USA
    Appl Radiat Isot 68:1950-8. 2010
    ..The overall synthesis time from EOB was 15-20 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 111-185 GBq/micromol...
  46. doi request reprint Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Appl Radiat Isot 67:2019-24. 2009
    ..The overall synthesis time from EOB was 15-20 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 111-185 GBq/micromol...
  47. doi request reprint The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3)
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, Room 202, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 21:245-9. 2011
    ..The synthetic strategy was to prepare a carbon-11-labeled maleic anhydride intermediate followed by the conversion to maleimide...
  48. doi request reprint Synthesis of carbon-11-labeled 4-aryl-4H-chromens as new PET agents for imaging of apoptosis in cancer
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Appl Radiat Isot 68:110-6. 2010
    ..The overall synthesis time from EOB was 15-20min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 111-185GBq/micromol...
  49. doi request reprint Simple synthesis of carbon-11 labeled styryl dyes as new potential PET RNA-specific, living cell imaging probes
    Min Wang
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202 2111, USA
    Eur J Med Chem 44:2300-6. 2009
    ..The specific activity of the target tracers [(11)C]6, [(11)C]7 and [(11)C]9 was in a range of 74-111GBq/mumol at the end of synthesis (EOS)...
  50. ncbi request reprint Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in cancers
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 16:5767-72. 2006
    ....
  51. ncbi request reprint Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer
    Jehana James
    Department of Medicine, Indiana University, Indianapolis, IN, USA
    Invest New Drugs 25:41-8. 2007
    ..We report the first phase I trials of 2-methoxyestradiol (2ME2, Panzem Capsules, EntreMed, Rockville, MD), alone and in combination with docetaxel, in patients with metastatic breast cancer (MBC)...
  52. ncbi request reprint Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase
    Ji Quan Wang
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 16:4102-6. 2006
    ..11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/micromol specific activity at end of bombardment (EOB)...
  53. doi request reprint Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 208, Indianapolis, IN 46202, USA
    Eur J Med Chem 46:4760-7. 2011
    ..These results encourage further in vivo evaluation of carbon-11-labeled celecoxib derivatives as new potential PET radiotracers for imaging of COX-2 expression in cancer...
  54. ncbi request reprint Redefining the target again: chemotherapeutics as vascular disrupting agents?
    Yesim Gokmen-Polar
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA
    Cancer Cell 14:195-6. 2008
    ..Addition of an anti-VEGFR2 antibody increased antitumor activity only in combination with CEP-mobilizing chemotherapeutics. Here we discuss the implications of this work...
  55. doi request reprint Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer
    Yesim Gokmen-Polar
    Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer Res Treat 127:375-84. 2011
    ..Our data demonstrate that dual targeting of EphA2 and ER is a promising approach for delaying resistance to Tamoxifen. The data support our hypothesis that EphA2 impacts ER function via a FAK dependent pathway...
  56. doi request reprint Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, Room 202, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 23:4342-6. 2013
    ..The synthetic strategy was to prepare a carbon-11-labeled Boc-protected intermediate followed by a quick acidic de-protection...
  57. ncbi request reprint Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents
    Min Wang
    Department of Radiology, Indiana University School of Medicine, 1345 West 16th Street, L 3 Room 202, Indianapolis, IN 46202, USA
    Appl Radiat Isot 65:1152-9. 2007
    ..0-6.0 Ci/mumol specific activity at EOB...
  58. doi request reprint Simple synthesis of carbon-11-labeled chromen-4-one derivatives as new potential PET agents for imaging of DNA-dependent protein kinase (DNA-PK) in cancer
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 202, Indianapolis, IN 46202, USA
    Appl Radiat Isot 70:1558-63. 2012
    ..The radiochemical yields decay corrected to end of bombardment (EOB), from [(11)C]CO(2), were 40-60%. The specific activity at end of synthesis (EOS) was 185-370 GBq/μmol...
  59. doi request reprint Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging
    Mingzhang Gao
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 202, Indianapolis, IN 46202 2111, USA
    Steroids 76:1505-12. 2011
    ..The overall synthesis time from EOB was 23 min, the radiochemical purity was >99%, and the specific activity at end of synthesis (EOS) was 277.5 ± 92.5 GBq/μmol (n = 5)...
  60. ncbi request reprint Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase
    Ji Quan Wang
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 15:4380-4. 2005
    ..2.2 followed by a simple chromatography methodology combined solid-phase extraction with high-performance liquid chromatography purification procedures in 15-25% radiochemical yields...
  61. ncbi request reprint Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers
    Mingzhang Gao
    Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 15:3865-9. 2005
    ....
  62. ncbi request reprint Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer
    Amelia E Hochreiter
    Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 46202 5251, USA
    Clin Cancer Res 12:3184-92. 2006
    ..The aim of this study was to address the breast cancer translational potential of the novel telomerase inhibitor, GRN163L...
  63. ncbi request reprint NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4
    Gregory Helbig
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Biol Chem 278:21631-8. 2003
    ..Taken together, these results implicate NF-kappaB in the migration and the organ-specific homing of metastatic breast cancer cells...
  64. ncbi request reprint Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents
    Qi Huang Zheng
    Department of Radiology, Indiana University School of Medicine, 975 West Walnut Street, Room 028C, Indianapolis, IN 46202 5121, USA
    Nucl Med Biol 29:761-70. 2002
    ....
  65. pmc Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer
    Suresh Kumar
    Departments of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Pathol 163:2531-41. 2003
    ..Taken together, these results suggest that cancer cell-derived cytokines, such as IL-1 alpha, induce cachexia by affecting leptin-dependent metabolic pathways...
  66. doi request reprint Synthesis of [¹¹C]PBR06 and [¹⁸F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO)
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, 1345 West 16th Street, L3 202, Indianapolis, IN 46202 2111, USA
    Steroids 76:1331-40. 2011
    ..Radiosynthesis of [(18)F]PBR06 using new tosylated precursor gave similar radiochemical purity, and higher specific activity, radiochemical yield and chemical purity in comparison with radiosynthesis using bromine precursor...
  67. doi request reprint [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C
    Min Wang
    Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Bioorg Med Chem Lett 21:1649-53. 2011
    ..The synthetic strategy was to prepare a carbon-11-labeled maleic anhydride intermediate followed by the conversion to maleimide...
  68. doi request reprint Development of new targeted therapies for breast cancer
    Danielle M Doyle
    Indiana University School of Medicine, Indianapolis, IN, USA
    Breast Cancer 15:49-56. 2008
    ..Indeed, each of these hallmarks presents a therapeutic opportunity. To believe otherwise would be to assume that a feature is both biologically crucial yet therapeutically unimportant, an unlikely paradox...
  69. ncbi request reprint Antiangiogenic agents in breast cancer
    John T Salter
    Division of Hematology Oncology, Indiana University, Indianapolis, Indiana, USA
    Cancer Invest 25:518-26. 2007
  70. ncbi request reprint Development of new targeted therapies for breast cancer
    Danielle M Doyle
    Indiana Cancer Pavillion, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer Treat Res 141:119-34. 2008
  71. doi request reprint Breast cancer in a wife: how husbands cope and how well it works
    Silvia M Bigatti
    Department of Public Health School of Medicine, 740 N Senate St, EF250, Indianapolis, IN 46202, USA
    Cancer Nurs 34:193-201. 2011
    ..Husbands of patients with breast cancer (HBCs) experience as much as or even more distress than patients. Husbands' coping strategies may predict their level of distress...
  72. ncbi request reprint Resistance in the anti-angiogenic era: nay-saying or a word of caution?
    Christopher J Sweeney
    Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
    Trends Mol Med 9:24-9. 2003
    ..Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer...
  73. ncbi request reprint Angiogenesis of breast cancer
    Bryan P Schneider
    Division of Hematology Oncology, Indiana University, 535 Barnhill Dr, RT 473 Indianapolis, IN 46202, USA
    J Clin Oncol 23:1782-90. 2005
  74. pmc Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study
    Changyu Shen
    Division of Biostatistics, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Cancer Inform 3:329-39. 2007
    ..In this report, we describe a comparative case study on the classification accuracy of hepatocellular carcinoma based on the serum proteomic pattern generated from a Surface Enhanced Laser Desorption/Ionization (SELDI) mass spectrometer...
  75. doi request reprint Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype
    Minsong Cao
    School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA
    IEEE Trans Med Imaging 28:861-71. 2009
    ..Monitoring variations in the tumor environment using DCE-CT offers an in vivo tool for the evaluation and optimization of new therapeutic strategies...
  76. doi request reprint Depression in husbands of breast cancer patients: relationships to coping and social support
    Silvia M Bigatti
    Department of Public Health, Indiana University School of Medicine, Indianapolis, IN, USA
    Support Care Cancer 19:455-66. 2011
    ..The purpose of the present study was to examine depression in husbands of women with breast cancer, as depression is typically as high in husbands as in patients, and impacts functioning in both...
  77. doi request reprint Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer
    Foluso O Ademuyiwa
    Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA
    Clin Breast Cancer 8:S151-6. 2008
    ....
  78. ncbi request reprint Thermoacoustic molecular imaging of small animals
    Robert A Kruger
    OptoSonics, Inc, 7210 Georgetown Road, Suite 400, Indianapolis, IN 46268, USA
    Mol Imaging 2:113-23. 2003
    ....
  79. ncbi request reprint Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue
    Lida Mina
    Department of Medicine, Indiana University, RT 473, Indianapolis, IN, 46202, USA
    Breast Cancer Res Treat 103:197-208. 2007
    ..We used paraffin-embedded core biopsies from a completed phase II trial to identify genes that correlate with response to primary chemotherapy...
  80. ncbi request reprint The potential and suitability of 2-methoxyestradiol in cancer therapy
    Carolyn Sidor
    Clin Cancer Res 11:6094-5; author reply 6095-6. 2005
  81. ncbi request reprint EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity
    Ming Lu
    Department of Basic Medical Sciences, Purdue University Cancer Center, West Lafayette, Indiana 47907, USA
    Cancer Res 63:3425-9. 2003
    ..These results have important implications for understanding the molecular basis underlying estrogen dependence and provide further evidence that EphA2 may provide a much-needed therapeutic target for breast cancer...
  82. ncbi request reprint A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
    Melody A Cobleigh
    Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    Semin Oncol 30:117-24. 2003
    ..The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy...
  83. ncbi request reprint Angiogenesis and antiangiogenic therapy
    George W Sledge
    Indiana University School of Medicine Indianapolis, USA
    Curr Probl Cancer 26:1-60. 2002
  84. doi request reprint Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
    ..This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC)...
  85. pmc Clinical-translational approaches to the Nm23-H1 metastasis suppressor
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 14:5006-12. 2008
    ....